Target- |
Mechanism- |
Active Org.- |
Originator Org.- |
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
牛磺熊去氧胆酸胶囊随机、开放、双周期、交叉人体生物等效性试验
[Translation] A randomized, open-label, two-cycle, crossover human bioequivalence trial of tauroursodeoxycholic acid capsules
以四川科伦药业股份有限公司提供的牛磺熊去氧胆酸胶囊为受试制剂,与原研厂家意大利贝斯迪大药厂生产的牛磺熊去氧胆酸胶囊为参比制剂,进行人体生物等效性试验,计算受试制剂的相对生物利用度,比较两种制剂的生物等效性。
[Translation] Taking tauroursodeoxycholic acid capsules provided by Sichuan Kelun Pharmaceutical Co., Ltd. as the test preparation, and the tauroursodeoxycholic acid capsules produced by the original manufacturer, Italy Besti Pharmaceuticals as the reference preparation, the human body was tested. The bioequivalence test calculates the relative bioavailability of the test preparation and compares the bioequivalence of the two preparations.
评价蓝楂酮苷胶囊治疗血脂异常的有效性与安全性的多中心、随机、双盲、安慰剂平行对照临床试验
[Translation] A multi-center, randomized, double-blind, placebo-controlled parallel clinical trial evaluating the efficacy and safety of Lanhazu Ketoside Capsules in the treatment of dyslipidemia
初步评价蓝楂酮苷胶囊治疗血脂异常的有效性与安全性;
探讨蓝楂酮苷胶囊不同剂量治疗血脂异常的临床疗效。
[Translation] Preliminary evaluation of the efficacy and safety of Lanhazu Ketoside Capsules in the treatment of dyslipidemia;
To investigate the clinical efficacy of Lanhau Ketoside Capsules with different doses in the treatment of dyslipidemia.
100 Clinical Results associated with Sichuan Pearl Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Sichuan Pearl Pharmaceutical Co., Ltd.
100 Deals associated with Sichuan Pearl Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Sichuan Pearl Pharmaceutical Co., Ltd.